FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Summary

FR901228 may stop the growth of cancer cells by blocking some of the enzymes needed for cell to grow and by blocking blood flow to the cancer. This phase II trial is studying how well FR901228 works in treating patients with relapsed or refractory non-Hodgkin's lymphoma.

Timeline

Start

2006-09

Primary completion

2011-04

Completion

2011-04

Drugs

Indications